Mara Caputo

Goeteborg, O, Sweden

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 14 publications

Inhibition of GCKIII kinases STK25 and MST3 mitigates organ lipotoxicity and enhances metabolic resilience under nutritional stress.

Inhibition of GCKIII kinases STK25 and MST3 mitigates organ lipotoxicity and enhances metabolic resilience under nutritional stress.

Journal: BMC medicine

Published: March 12, 2025

Therapeutic Potential of STE20-Type Kinase STK25 Inhibition for the Prevention and Treatment of Metabolically Induced Hepatocellular Carcinoma.

Therapeutic Potential of STE20-Type Kinase STK25 Inhibition for the Prevention and Treatment of Metabolically Induced Hepatocellular Carcinoma.

Journal: Cellular and molecular gastroenterology and hepatology

Published: November 12, 2024

GCKIII kinases control hepatocellular lipid homeostasis via shared mode of action.

GCKIII kinases control hepatocellular lipid homeostasis via shared mode of action.

Journal: Journal of lipid research

Published: June 27, 2024

Genetic Ablation of STE20-Type Kinase MST4 Does Not Alleviate Diet-Induced MASLD Susceptibility in Mice.

Genetic Ablation of STE20-Type Kinase MST4 Does Not Alleviate Diet-Induced MASLD Susceptibility in Mice.

Journal: International journal of molecular sciences

Published: January 23, 2024

Knockout of STE20-type kinase TAOK3 does not attenuate diet-induced NAFLD development in mice.

Knockout of STE20-type kinase TAOK3 does not attenuate diet-induced NAFLD development in mice.

Journal: Molecular medicine (Cambridge, Mass.)

Published: August 02, 2023

Silencing of STE20-type kinase TAOK1 confers protection against hepatocellular lipotoxicity through metabolic rewiring.

Silencing of STE20-type kinase TAOK1 confers protection against hepatocellular lipotoxicity through metabolic rewiring.

Journal: Hepatology communications

Published: July 29, 2022

GCKIII kinases in lipotoxicity: Roles in NAFLD and beyond.

GCKIII kinases in lipotoxicity: Roles in NAFLD and beyond.

Journal: Hepatology communications

Published: February 24, 2022

Inhibition of MAP4K4 signaling initiates metabolic reprogramming to protect hepatocytes from lipotoxic damage.

Inhibition of MAP4K4 signaling initiates metabolic reprogramming to protect hepatocytes from lipotoxic damage.

Journal: Journal of lipid research

Published: February 14, 2022

STE20-type kinase TAOK3 regulates hepatic lipid partitioning.

STE20-type kinase TAOK3 regulates hepatic lipid partitioning.

Journal: Molecular metabolism

Published: August 18, 2021

Silencing of STE20-type kinase STK25 in human aortic endothelial and smooth muscle cells is atheroprotective.

Silencing of STE20-type kinase STK25 in human aortic endothelial and smooth muscle cells is atheroprotective.

Journal: Communications biology

Published: August 16, 2021

Antagonizing STK25 Signaling Suppresses the Development of Hepatocellular Carcinoma Through Targeting Metabolic, Inflammatory, and Pro-Oncogenic Pathways.

Antagonizing STK25 Signaling Suppresses the Development of Hepatocellular Carcinoma Through Targeting Metabolic, Inflammatory, and Pro-Oncogenic Pathways.

Journal: Cellular and molecular gastroenterology and hepatology

Published: April 22, 2021

STE20-Type Protein Kinase MST4 Controls NAFLD Progression by Regulating Lipid Droplet Dynamics and Metabolic Stress in Hepatocytes.

STE20-Type Protein Kinase MST4 Controls NAFLD Progression by Regulating Lipid Droplet Dynamics and Metabolic Stress in Hepatocytes.

Journal: Hepatology communications

Published: November 11, 2020

Showing 1-12 of 14

Last Updated: 09/26/2026